ITMCTR1900002791尚未招募1 期
Multicenter clinical study for integrated traditional Chinese and Western medicine in the treatment of high risk MDS
The First affiliated Hospital of Zhejiang Chinese Medical University0 个研究点开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional study
入排标准
- 年龄范围
- 18 至 75（—）
- 性别
- All
入选标准
- •1) informed consent was obtained from the patient or his family;
- •2) according to WHO classification, IPSS-R prognosis was confirmed in high-risk MDS patients;
- •3) aged between 18 to 75 years;
- •4) Physical Strength Score (ECOG score 0-3;
- •5) liver and renal function: Bilirubin <=2 mg/dL 35 mol/L, AST/ALT less than 2 times the upper limit of the normal value, creatinine <=177 mol/l;
- •6) Cardiac function was acceptable: EF >50%;
- •7) predicted survival >=3 months.
排除标准
- •1) ECOG score>4;
- •2) serum Bilirubin > 2 Mgdl 35 Mol/L; ALT or AST > 2 x Upper limit of normal; Alkaline phosphatase > 3 ULN; Serum Creatinine > 177 Mol/L;
- •3) HIV test positive;
- •4) other serious diseases that may limit patients from participating in the trial (e.g. progressive infection, uncontrolled diabetes, severe cardiac insufficiency or Angina);
- •5) pregnant or lactating women or persons with General Conditions Not Suitable for chemotherapy;
- •6) who do not understand or follow the protocol.
研究者
相似试验
招募中
不适用
Anthropometric Evaluation of a New Asian Specific Knee Prosthesis - The Genesis II SlimACTRN12611000289910Smith & Nephew1,060
进行中（未招募）
不适用
A randomised, comparative, multicentre clinical trial of the immunogenicity and safety of Tdap-IPV vaccine (REPEVAX) and a tetanus monovalent vaccine in healthy adults 18 years of age and olderAntibody responses to tetanus toxoid.MedDRA version: 9.1Level: LLTClassification code 10060308Term: Tetanus antibody positiveEUCTR2008-008724-32-DESanofi Pasteur MSD S.N.C.456
进行中（未招募）
1 期
A randomised, comparative, multicentre clinical trial of the immunogenicity and safety of Tdap-IPV vaccine (REPEVAX) and a tetanus monovalent vaccine in healthy adults 18 years of age and olderEUCTR2008-008724-32-FRSanofi Pasteur MSD S.N.C.
进行中（未招募）
不适用
AN OPEN, RANDOMISED, MULTICENTRE, CLINICAL STUDY TO COMPARE THE SAFETY AND EFFICACY OF TACROLIMUS AND MINIMAL STEROIDS IN COMBINATION WITH EITHER A MONOCLONAL ANTI-IL2R ANTIBODY (DACLIZUMAB) OR MYCOPHENOLATE MOFETIL IN LIVER ALLOGRAFT TRANSPLANTATION - Marsilea (Mycophenolate mofetil or Antibodies with Reduced Steroids in Liver transplantation)Patients with hepatic disease who will undergo primary orthotopic liver or split liver allograft transplantation.MedDRA version: 7.0Level: LLTClassification code 10019650EUCTR2004-001617-34-GBAstellas Pharma Europe Ltd600
进行中（未招募）
不适用
AN OPEN, RANDOMISED, MULTICENTRE, CLINICAL STUDY TO COMPARE THE SAFETY AND EFFICACY OF TACROLIMUS AND MINIMAL STEROIDS IN COMBINATION WITH EITHER A MONOCLONAL ANTI-IL2R ANTIBODY (DACLIZUMAB) OR MYCOPHENOLATE MOFETIL IN LIVER ALLOGRAFT TRANSPLANTATION - Marsilea (Mycophenolate mofetil or Antibodies with Reduced Steroids in Liver transplantation)Patients with hepatic disease who will undergo primary orthotopic liver or split liver allograft transplantation.MedDRA version: 7.0Level: LLTClassification code 10019650EUCTR2004-001617-34-SEAstellas Pharma Europe Ltd600